ArticleBMC cancer2025
Development of a prognostic risk model for colorectal cancer based on microsatellite stability-associated genes.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) patients have a high recurrence rate, impacting survival. Microsatellite instability (MSI) is strongly linked to CRC development, making the MSI-related prognostic genes crucial for diagnosis and treatment.
methodsThis study used CRC datasets, including TCGA-CRC, GSE17537, GSE39582, and GSE18088. We analyzed differential expression between CRC and control samples, and between MSS and MSI-H samples. Key genes were identified through a co-expression network and used to develop a prognostic risk model. The model's performance was validated in GSE17537, and independent prognostic factors were identified to construct a survival nomogram. We also explored pathways linked to the risk groups and their association with the tumor immune microenvironment, and predicted potential therapeutic agents for CRC.
resultsWe identified 11 prognostic genes (CHGB, FABP4, PLIN4, PLIN1, RPRM, C7, AQP8, C2CD4A, APLP1, ADH1B, and CD36) and developed a CRC risk model that showed significant survival differences in the TCGA-CRC cohort and GSE17537, with AUCs over 0.6 at 3, 5, and 7 years. Independent prognostic factors included risk score, age, tumor stage, and pathological N, and a nomogram was created for survival prediction. The identified genes may influence CRC through various pathways and are linked to immune responses. Bleomycin emerged as a potential treatment, with CHGB and RPRM regulated by non-coding RNAs and transcription factors, possibly affecting CRC development.
conclusionsOur analysis of microsatellite stability-associated genes in CRC highlights their impact on TIME, clinicopathological features, and prognosis, providing new insights into predicting prognosis and developing personalized treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.